- Innoviva Reports First Quarter 2024 Financial Results; Highlights Recent Company Progress
- Innoviva to Participate in the BofA Securities Health Care Conference
- Innoviva Specialty Therapeutics’ Positive Phase 3 Oral Zoliflodacin Data for the Treatment of Uncomplicated Gonorrhea Announced at ESCMID Global 2024
- Innoviva Reports Fourth Quarter and Full Year 2023 Financial Results; Highlights Recent Company Progress
Key statistics
On Wednesday, Innoviva Inc (INVA:NSQ) closed at 16.08, -4.65% below its 52-week high of 16.87, set on Jan 04, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 16.07 |
---|---|
High | 16.22 |
Low | 15.88 |
Bid | 16.10 |
Offer | 16.50 |
Previous close | 16.15 |
Average volume | 622.56k |
---|---|
Shares outstanding | 62.44m |
Free float | 61.86m |
P/E (TTM) | 7.37 |
Market cap | 1.01bn USD |
EPS (TTM) | 2.19 USD |
Data delayed at least 15 minutes, as of May 22 2024 21:00 BST.
More ▼